[go: up one dir, main page]

WO2002003978A3 - A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES - Google Patents

A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES Download PDF

Info

Publication number
WO2002003978A3
WO2002003978A3 PCT/US2001/021557 US0121557W WO0203978A3 WO 2002003978 A3 WO2002003978 A3 WO 2002003978A3 US 0121557 W US0121557 W US 0121557W WO 0203978 A3 WO0203978 A3 WO 0203978A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
combination
treatment
agents useful
antidiabetic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021557
Other languages
French (fr)
Other versions
WO2002003978A2 (en
Inventor
Poelje Paul D Van
Mark D Erion
Toshihiko Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Metabasis Therapeutics Inc
Original Assignee
Sankyo Co Ltd
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002508433A priority Critical patent/JP2004508297A/en
Priority to AU2001273271A priority patent/AU2001273271B2/en
Priority to EP01952530A priority patent/EP1372660A2/en
Priority to HU0301830A priority patent/HUP0301830A3/en
Priority to IL15351301A priority patent/IL153513A0/en
Priority to SK6-2003A priority patent/SK62003A3/en
Priority to CA002412142A priority patent/CA2412142A1/en
Priority to AU7327101A priority patent/AU7327101A/en
Priority to KR1020037000126A priority patent/KR100854851B1/en
Application filed by Sankyo Co Ltd, Metabasis Therapeutics Inc filed Critical Sankyo Co Ltd
Priority to MXPA02012713A priority patent/MXPA02012713A/en
Priority to BR0112212-6A priority patent/BR0112212A/en
Priority to NZ523227A priority patent/NZ523227A/en
Publication of WO2002003978A2 publication Critical patent/WO2002003978A2/en
Priority to IL153513A priority patent/IL153513A/en
Priority to NO20030034A priority patent/NO20030034L/en
Anticipated expiration legal-status Critical
Publication of WO2002003978A3 publication Critical patent/WO2002003978A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.
PCT/US2001/021557 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES Ceased WO2002003978A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020037000126A KR100854851B1 (en) 2000-07-06 2001-07-05 Combination of FFP inhibitors and antidiabetics, useful for treating diabetes
EP01952530A EP1372660A2 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
MXPA02012713A MXPA02012713A (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES.
IL15351301A IL153513A0 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
SK6-2003A SK62003A3 (en) 2000-07-06 2001-07-05 A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CA002412142A CA2412142A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU7327101A AU7327101A (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP2002508433A JP2004508297A (en) 2000-07-06 2001-07-05 Combination agent of FBPase inhibitor and antidiabetic drug useful for treatment of diabetes
HU0301830A HUP0301830A3 (en) 2000-07-06 2001-07-05 Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU2001273271A AU2001273271B2 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
BR0112212-6A BR0112212A (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for treating diabetes.
NZ523227A NZ523227A (en) 2000-07-06 2001-07-05 A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
IL153513A IL153513A (en) 2000-07-06 2002-12-18 Pharmaceutical composition comprising a combination of a sulfonylurea antidiabetic agent and fbpase inhibitor and use thereof in the manufacture of medicaments for the treatment of diabetes
NO20030034A NO20030034L (en) 2000-07-06 2003-01-03 A combination of FBPase inhibitors and antidiabetic agents useful in the treatment of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003978A2 WO2002003978A2 (en) 2002-01-17
WO2002003978A3 true WO2002003978A3 (en) 2003-10-16

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021557 Ceased WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN100396283C (en)
AU (2) AU2001273271B2 (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ES2204170T3 (en) 1998-09-09 2004-04-16 Metabasis Therapeutics, Inc. NEW FRUCTOSA-1-6-BISFOSFATASA HETEROAROMATIC INHIBITORS.
IL151248A0 (en) 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
BR0212985A (en) 2001-09-24 2005-08-30 Imp College Innovations Ltd Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight
JP4733922B2 (en) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド Correction of eating behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PL1700856T3 (en) 2003-12-26 2016-05-31 Kyowa Hakko Kirin Co Ltd Thiazole derivative
KR20070053764A (en) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase
BRPI0519006A2 (en) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd use of a fbpase inhibitor, kit of a pharmaceutical composition, use of a biguanide preparation and a fbpase inhibitor, therapeutic agent for diabetes mellitus, and combination of therapeutic agents
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
TWI606848B (en) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (en) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
WO2001052825A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
WO2002000673A1 (en) * 2000-06-26 2002-01-03 Rodaris Pharmaceuticals Limited Phosphoglycan messengers and their medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6691498A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009163A2 (en) * 1989-01-24 1990-08-23 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2000014095A1 (en) * 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
WO2001052825A2 (en) * 2000-01-21 2001-07-26 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
WO2002000673A1 (en) * 2000-06-26 2002-01-03 Rodaris Pharmaceuticals Limited Phosphoglycan messengers and their medical uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

Also Published As

Publication number Publication date
EP1372660A2 (en) 2004-01-02
CZ20035A3 (en) 2003-05-14
HUP0301830A3 (en) 2007-10-29
CA2412142A1 (en) 2002-01-17
AU2001273271B2 (en) 2006-01-05
NZ523227A (en) 2005-04-29
PL365779A1 (en) 2005-01-10
CN100396283C (en) 2008-06-25
WO2002003978A2 (en) 2002-01-17
HUP0301830A2 (en) 2003-11-28
CN1599612A (en) 2005-03-23
BR0112212A (en) 2003-12-30
KR100854851B1 (en) 2008-08-27
IL153513A0 (en) 2003-07-06
RU2328308C2 (en) 2008-07-10
CN101301294A (en) 2008-11-12
MXPA02012713A (en) 2004-09-10
KR20030031952A (en) 2003-04-23
NO20030034D0 (en) 2003-01-03
SK62003A3 (en) 2003-09-11
AU7327101A (en) 2002-01-21
IL153513A (en) 2014-07-31
ZA200300044B (en) 2004-05-06
NO20030034L (en) 2003-03-05
JP2004508297A (en) 2004-03-18

Similar Documents

Publication Publication Date Title
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
WO2002064210A3 (en) Combination therapy comprising anti-diabetic and anticonvulsant agents
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001244399A1 (en) Gamma-secretase inhibitors
WO1999005096A3 (en) Urokinase inhibitors
YU34199A (en) Use of gastrointestinal lipase inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
AUPQ582400A0 (en) A method of treatment and agents for use therein
AU2001285334A1 (en) Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
AU1103699A (en) Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
WO2001000189A3 (en) Combination of mtp inhibitors and active agents that influence the metabolism and use thereof in medicaments
WO2001024784A3 (en) New use
HK1062634A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2412142

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012713

Country of ref document: MX

Ref document number: 153513

Country of ref document: IL

Ref document number: 523227

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001273271

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01873/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2003-5

Country of ref document: CZ

Ref document number: 2003/00044

Country of ref document: ZA

Ref document number: 200300044

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 62003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020037000126

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1200300101

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2003103436

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 2001952530

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018149243

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000126

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-5

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001952530

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523227

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523227

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001273271

Country of ref document: AU